Gan & Lee Pharmaceuticals. (SHA: 603087)

Gan & Lee Pharmaceuticals. Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	3,077	2,443	2,890	3,306	2,825	483.22
Short-Term Investments	-	-	201.36	276.44	945.34	201.62
Trading Asset Securities	1,793	2,410	1,636	1,624	787.05	1,058
Cash & Short-Term Investments	4,869	4,853	4,728	5,206	4,557	1,743
Cash Growth	5.93%	2.66%	-9.20%	14.24%	161.45%	47.94%
Accounts Receivable	377.32	385.37	189.57	934.66	827.35	847.53
Other Receivables	14.86	-	0.99	0.16	0.96	4.68
Receivables	392.18	385.37	190.55	934.82	828.3	852.21
Inventory	950.34	860.51	648.65	651.33	493.48	471.35
Other Current Assets	119.06	76.73	97.36	77.95	80.55	43.43
Total Current Assets	6,331	6,176	5,664	6,870	5,960	3,110
Property, Plant & Equipment	3,864	3,886	3,661	2,595	2,149	1,890
Long-Term Investments	439.66	304.66	-	201.36	466.05	362.2
Other Intangible Assets	275.36	278.08	293.48	295.99	238.92	131.85
Long-Term Deferred Tax Assets	157.01	168.95	138.25	30.8	14.93	-
Long-Term Deferred Charges	831.37	821.97	743.19	588.87	544.27	474.85
Other Long-Term Assets	54.2	79.99	106.51	270.33	134.67	57.38
Total Assets	11,953	11,715	10,607	10,853	9,507	6,027
Accounts Payable	96.32	94.82	36.52	26.15	14.79	19.11
Accrued Expenses	127.51	192.54	190	173.04	183.07	110.03
Current Portion of Leases	-	2.18	5.69	5.07	-	-
Current Income Taxes Payable	14.66	1.42	1.35	106.32	53.35	137.44
Current Unearned Revenue	30.87	52.99	68.13	36.56	68.44	90.69
Other Current Liabilities	491.98	429.49	511.36	138.39	90.19	100.96
Total Current Liabilities	763.71	773.45	813.04	485.53	409.85	458.22
Long-Term Leases	3.78	5.45	8.33	12.17	-	-
Long-Term Unearned Revenue	175.02	179.63	187.63	141.98	125.77	71.07
Long-Term Deferred Tax Liabilities	19.3	-	-	36.15	31.78	25.91
Other Long-Term Liabilities	13.65	14	12.27	10.2	1.69	0.68
Total Liabilities	975.47	972.52	1,021	686.02	569.09	555.88
Common Stock	601.2	594.16	565.65	561.54	561.54	360.9
Additional Paid-In Capital	3,516	3,351	2,563	2,476	2,474	72.69
Retained Earnings	7,044	6,865	6,525	7,133	5,905	5,035
Treasury Stock	-188.09	-71.36	-71.36	-	-	-
Comprensive Income & Other	3.68	3.82	3.44	-3.44	-1.55	2.18
Total Common Equity	10,977	10,743	9,586	10,167	8,939	5,471
Minority Interest	0	0	-0.16	-0.16	-0.16	-0.16
Shareholders' Equity	10,977	10,743	9,586	10,167	8,938	5,471
Total Liabilities & Equity	11,953	11,715	10,607	10,853	9,507	6,027
Total Debt	6.15	7.62	14.01	17.24	-	-
Net Cash (Debt)	4,863	4,846	4,714	5,189	4,557	1,743
Net Cash Growth	6.09%	2.80%	-9.16%	13.86%	161.45%	47.94%
Net Cash Per Share	8.38	8.55	8.37	9.25	8.55	3.45
Filing Date Shares Outstanding	572.15	590.05	561.54	561.54	561.54	505.26
Total Common Shares Outstanding	572.15	590.05	561.54	561.54	561.54	505.26
Working Capital	5,567	5,402	4,851	6,385	5,550	2,652
Book Value Per Share	19.19	18.21	17.07	18.11	15.92	10.83
Tangible Book Value	10,702	10,464	9,292	9,871	8,700	5,339
Tangible Book Value Per Share	18.70	17.73	16.55	17.58	15.49	10.57
Buildings	-	1,367	1,165	1,046	1,013	841.37
Machinery	-	1,474	1,237	1,263	1,171	1,014
Construction In Progress	-	2,007	2,003	874.91	410.12	383.12

Source: S&P Capital IQ. Standard template. Financial Sources.